Leukemia Therapeutics Treatment Market to Witness Robust Expansion Throughout the Forecast Period 2015 – 2025
Commercially available drug in the market for the treatment of leukemia includes Gleevec, Bosulif, Sprycel, Iclusig and others. Drugs which are in clinical trials expected to launch in the marketwithin next few (3 to 5)years include Bosutinib, Omapro, ga101/rg7159, Vidaza, Dacogen, Midostaurin, Vosaroxin, Quizartinib, Graspa, Marqibo.
Request For Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-421
The global market for leukemia treatment can be segmented as follows: Based on the developmental and progression rate, Chronic leukemia, Acute leukemia , Chronic leukemia is a type of blood cancer caused by uncontrolled growth of the WBC cells in our body. Chronic leukemia is a type of myeloproliferative disease which is characterized by the chromosomal translocation. Patients suffering from chronic leukemia show increased susceptibility to bacterial infections, thrombocytopenia and anemia and may also have enlarged spleen which causes pain on the left side. Incidence rate of chronic leukemia is high in men and is the second most common type of cancer occurring in male adults. Women who are above 50 years in age are expected to suffer from this chronic disease. Treatment for chronic leukemia depends on the phase of the disease that can be chronic, accelerated or the blast phase and the treatment for chronic leukemia includes chemotherapy, stem cell transplants and biologic therapies.
Acute myeloid leukemia develops at a speedy pace and is found in the blood and bone marrow. In the disease process, immature blood cells are present in the bone marrow. Symptoms found in patients due to the disease are flu, loss of weight, body ache, body pain and spots on skin.Treatment for acute leukemia includes chemotherapy, stem cell transplants and biologic therapies.
About 90% of the leukemia cases occur in the middle age and progresses with the aging. Therefore, leukemia therapeutics market is poised to grow with the rise in aging population and increasing incidences of leukemia. Drugs such as Bosulif, Gleevec, Sprycel andIclusigare commercially available for the treatment of leukemia. Gleevec was the first leukemia drug introduced in 2001, since then there has been a revolutionary change in the quality life of patients as compared to the former chemotherapy drugs.Globally the numbers of elderly people, 60 years and above are growing and it is expected that this age group will cross the 2 billion mark in 2050 stated by United Nations Population Division. Hence the leukemia therapeutics market will also grow significantly.However adverse event (cytotoxic) associated with nearly all kinds of leukemia therapeutics treatment might restrict the global market demand of leukemia therapeutics market.
North America dominates the global market for leukemia therapeutics treatment due to high prevalence rate of leukemia (acute, chronic) and extensive technological advancement (diagnosis) in this region. Europe represents the second largest market share due to its large geriatric population base. In addition Asia-Pacific and RoW hold the third and fourth position in the global leukemia therapeutics market respectively due to less prevalence rate of leukemia and lack of proper healthcare facilities in few Asian and African countries.
North America accounted for 62% sales of leukemia drugs in the therapeutics market during 2010 followed by Europe and Asia Pacific. Leukemia therapeutics market will grow significantlyand the total growth will depend on pipeline products and metabolic inhibitors, a tyrosine kinase receptor FLT -3 of Novartis and some other capable molecules, improving the therapeutics market.
Request to View TOC @ https://www.futuremarketinsights.com/toc/rep-gb-421
Major market playerscontributing the global market share of leukemia therapeutics treatment includes Ambit Biosciences Corporation, AriadPharmaceuticals,Inc., Biogen Idec, Inc., Novartis Pharmaceuticals, Bristol-Myers Squibb, Pfizer and others.
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.
FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customised and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leukemia Therapeutics Treatment Market to Witness Robust Expansion Throughout the Forecast Period 2015 – 2025 here
News-ID: 1461636 • Views: 209
More Releases from Future Market Insights
Future Market Insights Appoints Aditi Basu as Chief Marketing Officer
DUBAI, UAE, October 5, 2021 -- Future Market Insights (FMI), an award-winning market research & consulting firm, announces the appointment of Mrs. Aditi Basu as Chief Marketing Officer (CMO). Aditi will be responsible for leading the marketing strategy for MarketNgage, the revolutionary intelligence engine of Future Market Insights, purpose-built for disparate market research needs of today’s businesses. Aditi has over fifteen years of experience in corporate strategy and go-to-market advisory. She
Ferrovanadium Market to Witness Robust Expansion throughout the Forecast 2018-20 …
Future Market Insights (FMI) analyses the global ferrovanadium market in its new publication titled “Ferrovanadium Market: Global Industry Analysis (2013 – 2017) & Opportunity Assessment (2018 – 2028)”. This study provides data for 2017 along with the forecast for the period (2018–2028). The main objective of the report is to identify the dynamics of the market and provide recent updates and insights pertaining to various segments of the global ferrovanadium
Automotive Lighting Market is expected to grow at a CAGR of ~6% during the forec …
In a recent publication, Future Market Insights (FMI) provides a perspective on the growth trajectory of automotive lighting market for the period between 2019 and 2029. According to the study, worldwide sales of automotive lighting reached ~2 billion units, equating a value of ~US$ 36.5 billion in 2018. Gains remain driven by growing popularity of luxury cars and high purchasing power of middle class demographic in developing countries that increased the
Motorcycle Suspension System Market Size, Share, Industry Analysis, Future Growt …
Future Market Insights has released a new market study on "Motorcycle Suspension System Market: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028", which studies the global Motorcycle Suspension System market and offers deep dive analysis for the next ten years. The report evaluates all the key macro-economic factors projected to support the growth of the global as well as regional markets. The report on Motorcycle Suspension System also presents the
More Releases for Leukemia
Global Leukemia Therapeutics Market Continued Growth Report
The “Global Leukemia Therapeutics Market Continued Growth Report” Latest added Leukemia Therapeutics Market research study by Zion Market Research offers detailed product outlook and elaborates market review till 2026. , The Leukemia Therapeutics Market is the most blooming and promising sector of the industry. This overall Leukemia Therapeutics Market has been ascending at a higher rate with the enhancement of inventive strategies and a raising customer tendency. The wide-coming to
Juvenile Myelomonocytic Leukemia Therapeutics- Pipeline Analysis 2018
Juvenile myelomonocytic leukemia is a rare disease that occurs mostly in the children who are under four years of age. The abnormal growth of the monocytes results in the accumulation of monocytes in the bone marrow. Download the sample report @ https://www.pharmaproff.com/request-sample/1116 This leads to improper functioning of the bone marrow. The actual cause of juvenile myelomonocytic leukemia is still unknown; however, mutation in the RAS gene is observed in patients
Acute Myeloid Leukemia Market Growth by 2021
Acute Myeloid Leukemia (AML) is classed as an orphans disease. AML is a rare but a severe disease and is a most common leukemia. It is primarily a disease of the elderly, with an average age of diagnosis of approximately 66. AML results from the acquired changes in the DNA of a developing marrow cell. The marrow cells get converted into the leukemic cells, multiplies into 11 billion or more.
Acute Leukemia Therapeutics Pipeline Analysis
Acute leukemia is also known as cancer of blood cells in which immature blood cells modify into cancer cells. The disease arises from bone marrow and causes formation of numerous large blood cells. Leukemia is categorized into five different types namely acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and hairy cell leukemia. Leukemia can produce be symptoms such as fever, recurrent nosebleeds, bone pain, swollen
Leukemia Therapeutics Market – Global Industry Insights, 2025
Leukemia is a cancer of blood cells and therefore, are occasionally referred to as ‘blood cancer’. Most blood cells are formed in the bone marrow. In leukemia, undeveloped blood cells become cancer. Leukemia can be either acute or chronic. Acute leukemia is a fast growing cancer, which usually gets worse rapidly. Chronic leukemia is a slow growing cancer, which gets worse slowly over time period. The treatment and diagnosis of
New dynamics in monitoring diagnostics in leukemia
Dresden/Germany Diagnosis leukemia and stem cell transplantation The diagnosis "leukemia" for patients means to undergo several stressful therapeutic interventions. If chemotherapy is not effective, stem cell transplantation mostly is the last chance for healing. However, a sudden graft rejection or disease relapse can always occur despite the successful transfer of the hematopoietic stem cells from donor to recipient. Therefore, the regular quantitative assessment of the donor and recipient cell-portion in the blood